-
Ocrevus fuels a sea change in the treatment of multiple sclerosis in U.S.
Genentech‘s Ocrevus (ocrelizumab), approved in March 2017, has fueled a sea change in the treatment of multiple sclerosis (MS) patients in the U.S., leading to an increased interest in disease-modifying therapies (DMTs) for progressive forms of MS.
Now, other potential treatment choices for progressive MS forms will likely follow, including Novartis’ investigative oral treatment siponimod (BAF312), MedDay Pharmaceuticals‘ MD-1003, and AB Science‘s masitinib. Click here to read more: After Ocrevus Approval, New Therapies May Become Available for MS, Report Suggests
Have you heard of these therapies? What do you think about them?
Sorry, there were no replies found.
Log in to reply.